• 出版社/出版日：Mordor Intelligence / 2020年4月20日
|Single User||￥480,250 (USD4,250)||▷ お問い合わせ|
|Team User||￥536,750 (USD4,750)||▷ お問い合わせ|
|Corporate License||￥847,500 (USD7,500)||▷ お問い合わせ|
Urinalysis market is expected to exibhit a growth of 7.5% CAGR during the forecast period. The higher burden of chronic diseases and rising adaptation of point of care testing is expected to be the major contributing factors for the market growth. Urinary tract infection refers to the infection in any part of the urinary system. According to the Therapeutic Advances in Urology, urinary tract infections are commonly found in the women with a global incidence of around 50% – 60% in adult women, in 2019. Furthermore, according to the study of Parasites and Vectors, 2019, which evaluated the Clinitek (manufactured by Siemens Healthineers) for its efficacy. Clinitek is a point-of-care testing that automatically checks the humidity exposure and other parameters. The results for this evaluation was observed that the device was enable to successfully detect the haematuria and nitrites. Hence, these factors are expected to fuel the growth of urinalysis market.
Key Market Trends
Automated Analysers Segment is Expected to Hold a Major Market Share in the Market
Automated analyzers segment is expected to hold a major market share in the urinalysis treatment owing to technological advancments in the product. For instance, in 2018, Beckman Coulter and Arkray Inc. patnered to develop iQ Urinalysis Workcell for urinalysis testing. It involves a morphology imaging system and a automated analyzer. Furthermore, according to the study published, in 2019, by Journal of Clinical Laboratory Analysis, the automated analyzers were found to be more efficient and effective for urinalysis.
Also, higher prevalence of diabetes is expected to boost up the demand for automated analyzers. According to International Diabetes Federation, in 2019, around 429.9 million people were diagnosed with diabetes. Hence, aforementioned factors are expected to propel the urinalysis market grwoth.
North America is Expected to Hold a Significant Share in the Market
North America is expected to hold a major market share in the global urinalysis market due to increasing aging population and higher prevalence of chronic kidney diseases. Chronic kidney disease is associated with the kidney failure. According to National Kidney Foundation, chronic kidney disease causes more death than breast cancer and prostate cancer. Currently, around 37 million people are affected with it. It is more prevalent in older population, affecting approximately 15% of the adult population. Hence, this emerges the need for proper diagnosis and treatment of chronic kidney diseases and thereby these factors are expected to boost the demand for urinalysis market.
Companies are taking strategic initiatives to grow their presence in the urinalysis market. For instance, in 2016, Sysmex launched UD-10 Fully-Automated Imaging for testing of sediment urinalysis. Currently the market is dominated by few players such as Cardinal Health Inc., Alere (Abbott Laboratories), Beckman Coulter Inc., Siemens Healthineers, Roche Diagnostics, Sysmex Corporation, Bio-Rad Laboratories Inc., Arkray Inc., Acon Laboratories Inc., and Becton, Dickinson and Company.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Chronic Kidney Disease
4.2.2 Rising Preference for Point of Care Testing
4.3 Market Restraints
4.3.1 Stringent Regulatory framework
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
126.96.36.199 Automated Analyser
188.8.131.52 Semi-automated Analyzer
184.108.40.206 Point of Care Analyzer
220.127.116.11 Reagents & Kits
5.2 By Test Type
5.2.2 Pregnancy & Fertility
5.3 By Application
5.3.1 Disease Screening
5.3.2 Pregnancy & Fertility
5.4.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle-East and Africa
5.4.5 South America
22.214.171.124 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories (Alere)
6.1.2 Acon Laboratories Inc.
6.1.3 Arkray Inc.
6.1.4 Beckman Coulter Inc.
6.1.5 Becton, Dickinson and Company
6.1.6 Bio-Rad Laboratories Inc.
6.1.7 Cardinal Health Inc.
6.1.8 Roche Diagnostics
6.1.9 Siemens Healthineers
6.1.10 Sysmex Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS